Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jun Yatsunami is active.

Publication


Featured researches published by Jun Yatsunami.


Preventive Medicine | 1992

Anticarcinogenic effects of (−)-epigallocatechin gallate☆☆☆

Hirota Fujiki; Seiji Yoshizawa; Takahiko Horiuchi; Masami Suganuma; Jun Yatsunami; Shinji Nishiwaki; Sachiko Okabe; Rie Nishiwaki-Matsushima; Takuo Okuda; Takashi Sugimura

BACKGROUNDnOur research objective is to develop nontoxic cancer chemopreventive agents and to apply these agents in treating humans. We are identifying agents that inhibit the process of tumor promotion in two-stage carcinogenesis experiments on mouse skin.nnnMETHODSnWe review (a) the inhibitory effect of penta-O-galloyl-beta-D-glucose (5GG) on tumor promotion by teleocidin, one of the 12-O-tetradecanoylphorbol-13-acetate (TPA)-type tumor promoters (5GG is structurally similar to (-)-epigallocatechin gallate (EGCG) and is isolated from hydrolyzed tannic acid); (b) the inhibitory effects of EGCG, the main constituent of Japanese green tea, on tumor promotion with two tumor promoters, teleocidin and okadaic acid, a non-TPA-type tumor promoter; (c) the mechanisms of action of EGCG, a single application of which reduced the specific binding of [3H]TPA and [3H]okadaic acid to a particulate fraction of mouse skin; and (d) the anticarcinogenic effects of EGCG on duodenal carcinogenesis induced by N-ethyl-N-nitro-N-nitrosoguanidine in male C57BL/6 mice. EGCG is a nontoxic compound.nnnCONCLUSIONnWe believe that the main constituent of Japanese green tea, EGCG, is a practical cancer chemopreventive agent available in everyday life.


Biochemical and Biophysical Research Communications | 1991

Vimentin is hyperphosphorylated in primary human fibroblasts treated with okadaic acid

Jun Yatsunami; Hirota Fujiki; Masami Suganuma; Seiji Yoshizawa; John E. Eriksson; Mark O. J. Olson; Robert D. Goldman

Okadaic acid and dinophysistoxin-1 (35-methylokadaic acid) induced hyperphosphorylation of a 58 kDa protein in primary human fibroblasts, due to inhibition of protein phosphatase 1 and 2A activities. The protein was present in the nuclear and cytosolic fractions. Its pI was 5.3. The hyperphosphorylated protein reacted with monoclonal and polyclonal anti-vimentin antibodies, but not with anti-nucleolin antibody. Phosphorylation of vimentin was stimulated in vitro by dinophysistoxin-1 dose-dependently in the presence of protein phosphatase 2A and protein kinases.


Toxicon | 1991

Binding competition of okadaic acid derivatives to anti-okadaic acid antibody

Jun Yatsunami; Hirota Fujiki; Masami Suganuma; Shinji Nishiwaki; Makoto Ojika; Kiyoyuki Yamada; Lawrence Levine

The serologic activities of structurally related okadaic acid derivatives have been determined. Binding of [3H]okadaic acid to rabbit anti-okadaic acid is inhibited with equal effectiveness by okadaic acid, dinophysistoxin-1, acanthifolicin, okadaic acid tetramethyl ether, and okadaic acid spiroketal II. Okadaic acid spiroketal I, which lacks the F- and G-rings of okadaic acid, inhibits serologic binding about 60 times less effectively. The F- and G-rings of okadaic acid may comprise part of the epitopes recognized by some of the polyclonal antibodies.


Cancer Research | 1993

Tumor Necrosis Factor Acts as a Tumor Promoter in BALB/3T3 Cell Transformation

Atsumasa Komori; Jun Yatsunami; Masami Suganuma; Sachiko Okabe; Saori Abe; Ayako Sakai; Kiyoshi Sasaki; Hirota Fujiki


Japanese Journal of Clinical Oncology | 1993

Anticarcinogenic Activity of Green Tea Polyphenols

Atsumasa Komori; Jun Yatsunami; Sachiko Okabe; Saori Abe; Katsuhiro Hara; Masami Suganuma; Seong-Jin Kim; Hirota Fujiki


Carcinogenesis | 1992

Hyperphosphorylation of cytokeratins 8 and 18 by microcystin-LR, a new liver tumor promoter, in primary cultured rat hepatocytes

Tetsuya Ohta; Rie Nishiwaki; Jun Yatsunami; Atsumasa Komori; Masami Suganuma; Hirota Fujiki


Cancer Research | 1993

Hyperphosphorylation of retinoblastoma protein and p53 by okadaic acid, a tumor promoter

Jun Yatsunami; Atsumasa Komori; Tetsuya Ohta; Masami Suganuma; Hirota Fujiki


Carcinogenesis | 1992

An alternative theory of tissue specificity by tumor promotion of okadaic acid in glandular stomach of SD rats

Masami Suganuma; Masae Tatematsu; Jun Yatsunami; Shigeru Yoshizawa; Sachiko Okabe; Daisuke Uemura; Hirota Fujiki


Cancer Research | 1993

Hyperphosphorylation of cytokeratins by okadaic acid class tumor promoters in primary human keratinocytes.

Jun Yatsunami; Atsumasa Komori; Tetsuya Ohta; Masami Suganuma; Stuart H. Yuspa; Hirota Fujiki


Progress in Clinical and Biological Research | 1992

Specific mechanistic aspects of animal tumor promoters: the okadaic acid pathway.

Hirota Fujiki; Masami Suganuma; Shinji Nishiwaki; Seiji Yoshizawa; Jun Yatsunami; Matsushima R; Furuya H; Okabe S; Shigeki Matsunaga; Sugimura T

Collaboration


Dive into the Jun Yatsunami's collaboration.

Top Co-Authors

Avatar

Hirota Fujiki

Argonne National Laboratory

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mark O. J. Olson

University of Mississippi Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge